Evotec (NASDAQ:EVO - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Tuesday, May 6th. Analysts expect Evotec to post earnings of ($0.11) per share and revenue of $215.09 million for the quarter.
Evotec Price Performance
NASDAQ:EVO traded up $0.06 during trading hours on Friday, hitting $4.29. 55,605 shares of the company were exchanged, compared to its average volume of 127,894. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. Evotec has a 52-week low of $2.84 and a 52-week high of $5.68. The company's 50 day moving average price is $3.62 and its 200-day moving average price is $4.13.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.
Read Our Latest Analysis on EVO
Institutional Trading of Evotec
A hedge fund recently raised its stake in Evotec stock. Bank of America Corp DE raised its holdings in Evotec SE (NASDAQ:EVO - Free Report) by 262.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,828 shares of the company's stock after purchasing an additional 9,289 shares during the quarter. Bank of America Corp DE's holdings in Evotec were worth $53,000 at the end of the most recent reporting period. 5.81% of the stock is currently owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
